-
Most Recent
Search Results
240 results for icgn
Cynicism and Conspiracy Theories Could Help Ocugen
While OCGN stock seems well behind the vaccination race to be worth a shot, there is one narrative that could potentially help.
Ocugen Stock Is Essentially Back to Being an Eye Disease Play
OCGN stock has a tough path to entry in the North American market and time is not on its side
What the WHO Snub Means For Ocugen Stock Investors?
Add the World Health Organization’s suspension of Covaxin to the list of troubles that are weighing down OCGN stock.
If the FDA Can’t Help Ocugen Stock, You Have to Wonder Who Can
Because of the pandemic, OCGN stock attracts speculative interest. But it is not likely to pay off in the long-run
Ocugen Just Overcame a Serious Hurdle
OCGN stock has skyrocketed on positive Phase 3 results. But the company is facing tough competition.
Ocugen Proves Groupthink Is a Double-Edged Sword
While OCGN stock is an intriguing idea on the science, when the masses have a different framework, it becomes a risky proposition.
ImmunoGen Stock Is in Trouble Going Into Earnings
IMGN stock is falling into a bottomless pit, but therein lies an opportunity. You can take a bet on a surprise upside run in ImmunoGen.
Don’t Chase Ocugen Stock Without Reading the Fine Print
OCGN stock has soared on positive vaccine data. But investors must remember that Ocugen’s market and experience are sharply limited.
Apple News: The New Racially Diverse Emoji Are Here (in Beta)
Apple’s new racially diverse emoji are available in its newest iOS 8.3 beta and they include six different skin tones to represent races.
It’s Time to Get Clinical, Not Cynical, With Ocugen Stock
The selling pressure on OCGN stock has been as heavy as a rock, but worried shareholders should celebrate Ocugen’s breakthrough moments.
Ocugen Investors Are Betting On a Horse Than Can’t Win the Race
OCGN stock has declined to a level where a bounce is certainly possible, but not likely as Ocugen fails to demonstrate any profitability.
With No Vaccine Approval, Ocugen Is the Definition of Dead Money
Holding out hope for a Covid vaccine approval that might never come, OCGN stock is too risky while the company has no revenue.
Ocugen Needs More Than Covaxin to Boost Its Falling Shares
A doomed-looking vaccine partnership puts Ocugen back in the business of obscurity and OCGN stock at risk of much lower prices.
Anticipation of Better Vaccine News Could Drive Ocugen Higher
From a December low of 29 cents, OCGN stock now trades at about $11, a return of over 3600%. Not bad for a name that…
Ocugen Stock: The Two What-If Scenarios To Consider
OCGN stock is now facing an all or nothing business development and is at a very critical stage so it is wise to avoid it.
OCGN Stock: 3 Key Catalysts That Could Send This Stock Soaring Again
Investors in OCGN stock have seen shares settle down quite a bit of late, but there’s room to be optimistic with this biotech stock.
Prepare for Another Pop to $15 With Ocugen Stock
Even while Ocugen changes up its strategy in the U.S., the company is pushing for approval elsewhere and OCGN stock can still move higher.
Ocugen Stock Is Well-Positioned, But Investors Want Results
The company’s latest business update sounds all fine and good, but OCGN stock holders want to see some action, not just words.
OCGN Stock Plunges After WHO Delays Decision on COVAXIN Vaccine
OCGN stock is capping off a day full of gains with a finish in the red. Late afternoon misfortune caused the stock to tank in…
A New Orphan Drug Designation Gives Hope to Ocugen Stock
The FDA just gave a special designation to one of Ocugen’s flagship products. That is good for science and it’s great for OCGN stock.
Sell Ocugen Stock Before the Other Shoe Finally Drops
The bad news with Covaxin hasn’t sunk in yet with OCGN stock investors, so get out while the stock still remains elevated.
Ocugen Stock Has Way More Downside, Even After This Deep Correction
OCGN stock looks unattractive even after a big correction from highs. Vaccine space looks crowded in the U.S. and Ocugen might not benefit.
Volatile Ocugen Stock Is an Incredibly Risky Covid-19 Vaccine Play
The bear case for OCGN stock is more compelling, given the scant details surrounding the Indian Covid-19 vaccine it seeks to commercialize.
7 – 10 of 240 results
